Immunization with *Brucella* VirB Proteins Reduces Organ Colonization in Mice through a Th1-Type Immune Response and Elicits a Similar Immune Response in Dogs

Cora N. Pollak, María Magdalena Wanke, Silvia M. Estein, M. Victoria Delpino, Norma E. Monachesi, Elida A. Comercio, Carlos A. Fossati, Pablo C. Baldi

Instituto de Estudios de la Inmunidad Humoral (IDEHU, CONICET-UBA), Cátedra de Inmunología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina; Servicio de Teriogenología, Facultad de Ciencias Veterinarias, Universidad de Buenos Aires, Buenos Aires, Argentina; Laboratorio de Inmunología, Departamento de Sanidad Animal y Medicina Preventiva, Centro de Investigación Veterinaria de Tandil (CIVETAN, CONICET), Facultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires, Tandil, Argentina

VirB proteins from *Brucella* spp. constitute the type IV secretion system, a key virulence factor mediating the intracellular survival of these bacteria. Here, we assessed whether a Th1-type immune response against VirB proteins may protect mice from *Brucella* infection and whether this response can be induced in the dog, a natural host for *Brucella*. Splenocytes from mice immunized with VirB7 or VirB9 responded to their respective antigens with significant and specific production of gamma interferon (IFN-γ), whereas interleukin-4 (IL-4) was not detected. Thirty days after an intraperitoneal challenge with live *Brucella abortus*, the spleen load of bacteria was almost 1 log lower in mice immunized with VirB proteins than in unvaccinated animals. As colonization reduction seemed to correlate with a Th1-type immune response against VirB proteins, we decided to assess whether such a response could be elicited in the dog. Peripheral blood mononuclear cells (PBMCs) from dogs immunized with VirB proteins (three subcutaneous doses in QuilA adjuvant) produced significantly higher levels of IFN-γ than cells from control animals upon *in vitro* stimulation with VirB proteins. A skin test to assess specific delayed-type hypersensitivity was positive in 4 out of 5 dogs immunized with either VirB7 or VirB9. As both proteins are predicted to locate in the outer membrane of *Brucella* organisms, the ability of anti-VirB antibodies to mediate complement-dependent bacteriolysis of *B. canis* was assessed in *vitro*. Sera from dogs immunized with either VirB7 or VirB9, but not from those receiving phosphate-buffered saline (PBS), produced significant bacteriolyis. These results suggest that VirB-specific responses that reduce organ colonization by *Brucella* in mice can be also elicited in dogs.

Brucellosis is caused by Gram-negative bacteria of the genus *Brucella*, which infect different domestic and wild animals but can also spread to humans, producing a systemic febrile illness sometimes accompanied by localized complications (1). As humans usually acquire the infection through contact with infected animals, their tissues (e.g., placental tissue), or their products (usually dairy products), prevention of the infection in host animals is an adequate strategy to prevent human brucellosis. No vaccine is currently available to prevent canine brucellosis due to *Brucella abortus*, the spleen load of bacteria in mice was almost 1 log lower in mice immunized with VirB proteins than in unvaccinated animals. As colonization reduction seemed to correlate with a Th1-type immune response against VirB proteins, we decided to assess whether such a response could be elicited in the dog. Peripheral blood mononuclear cells (PBMCs) from dogs immunized with VirB proteins (three subcutaneous doses in QuilA adjuvant) produced significantly higher levels of IFN-γ than cells from control animals upon *in vitro* stimulation with VirB proteins. A skin test to assess specific delayed-type hypersensitivity was positive in 4 out of 5 dogs immunized with either VirB7 or VirB9. As both proteins are predicted to locate in the outer membrane of *Brucella* organisms, the ability of anti-VirB antibodies to mediate complement-dependent bacteriolysis of *B. canis* was assessed in *vitro*. Sera from dogs immunized with either VirB7 or VirB9, but not from those receiving phosphate-buffered saline (PBS), produced significant bacteriolyis. These results suggest that VirB-specific responses that reduce organ colonization by *Brucella* in mice can be also elicited in dogs.
The expression of virB genes is induced intracellularly in the first hours after uptake of *Brucella* by macrophages (24, 25). Since most brucellae die during the initial phase of intracellular establishment, we hypothesize that infected macrophages probably display peptides derived from VirB proteins in the context of major histocompatibility complex class II (MHC-II) molecules on the cellular surface. In this context, VirB-specific Th1 cells might recognize infected macrophages and respond with the production of IFN-γ, leading to the activation of macrophagic antimicrobial mechanisms.

The main goals of the present study were to assess whether the induction of a Th1-type immune response against VirB proteins may protect mice from *Brucella* infection and whether this type of response can be induced in the dog, a natural host for *Brucella*.

**MATERIALS AND METHODS**

**Antigen production.** *Escherichia coli* strain JM109 (Promega, Madison, WI) was used as the host for propagation of plasmids. Strain BL21(DE3) (Stratagene, La Jolla, CA) was used for expression of the recombinant proteins. Bacterial strains were routinely grown at 37°C in Luria-Bertani (LB) broth or agar, supplemented when required with 100 μg/ml of ampicillin. The plasmids pTrHis-FusB7 A R and pTrHis-FusB9 A R containing the VirB7 and VirB9 genes, respectively, with the addition of a poly(H) tail, were kindly provided by Diego Comerci, UNSAM, Argentina. Competent *E. coli* BL21(DE3) colonies were transformed with these plasmids. Ampicillin-resistant colonies containing the pTrHis-FusB7 A R and pTrHis-FusB9 A R plasmid were grown in Terrific broth medium containing 100 μg of ampicillin/ml at 37°C with agitation (160 rpm) until reaching an optical density at 600 nm (OD600) of 1.0. A 0.25 endotoxin unit/well of substrate is used to assess the results. After centrifugation, soluble protein was purified from the supernatant appropriately to determine the number of CFU from each group of experimental mice and the control group. The purity of both proteins was assessed by SDS-polyacrylamide gel electrophoresis followed by Coomassie blue staining. Purified proteins were incubated with polymerin B-Sepharose overnight at 4°C with agitation to eliminate lipopolysaccharide (LPS) contamination. The residual content of LPS in these preparations, according to the *Limulus* amebocyte assay (Assays of Cape Cod, Woods Hole, MA), was <0.25 endotoxin unit/μg protein. The protein concentrations of the antigen preparations were determined by the bicinchoninic acid method (Pierce, Rockford, IL) using bovine serum albumin as the standard. The purity of both proteins was assessed by SDS-polyacrylamide gel electrophoresis followed by Coomassie blue staining. Purified proteins were incubated with polymerin B-Sepharose overnight at 4°C with agitation to eliminate lipopolysaccharide (LPS) contamination. The residual content of LPS in these preparations, according to the *Limulus* amebocyte assay (Assays of Cape Cod, Woods Hole, MA), was <0.25 endotoxin unit/μg protein. The protein concentrations of the antigen preparations were determined by the bicinchoninic acid method (Pierce, Rockford, IL) using bovine serum albumin as the standard. The purity of both proteins was assessed by SDS-polyacrylamide gel electrophoresis followed by Coomassie blue staining. Purified proteins were incubated with polymerin B-Sepharose overnight at 4°C with agitation to eliminate lipopolysaccharide (LPS) contamination. The residual content of LPS in these preparations, according to the *Limulus* amebocyte assay (Assays of Cape Cod, Woods Hole, MA), was <0.25 endotoxin unit/μg protein. The protein concentrations of the antigen preparations were determined by the bicinchoninic acid method (Pierce, Rockford, IL) using bovine serum albumin as the standard.

**Brucella strains.** *B. abortus* 544 (smooth virulent strain), and a local clinical isolate of *B. canis* were obtained from our laboratory collection. Bacteria were cultured in tryptose-soy agar (Merck, Buenos Aires, Argentina) supplemented and incubated as described previously (11, 26). *Brucella* strain manipulations were performed in biosafety level 3 facilities.

**Experiments in mice.** (i) Animals. Female BALB/c mice (8 to 9 weeks old), obtained from the University of La Plata, Argentina, were acclimated and randomly distributed into experimental groups. The mice were kept in conventional animal facilities and received water and food ad libitum. After inoculation with *B. abortus* 544, mice were kept in biosafety level 3 animal facilities. Experiments in mice were approved by our institutional animal care and use committee.

(ii) *Immunization and challenge.* Groups of 10 mice were immunized by the intraperitoneal (i.p.) route at day 0 with 30 μg of VirB7 or VirB9 in complete Freund’s adjuvant (Sigma) and 15 days later with the same dose of antigens in incomplete Freund’s adjuvant. On both occasions, another group of mice (negative control) received an equal volume of PBS with the same adjuvant. As a positive control for the protection experiments, other groups of mice were immunized once i.p. at day 0 with heat-killed *B. melitensis* H38 (8 × 10⁸ CFU) in incomplete Freund’s adjuvant or with viable *B. abortus* S19 (vaccine strain, 1.2 × 10⁹ CFU). Blood samples were collected from mice by submandibular puncture at the time of the first immunization (day 0), at the second immunization (day 15), and at day 45. At this later time point (30 days after the last immunization), mice from each group were challenged i.p. with virulent *Brucella* organisms (4 × 10⁴ CFU of *B. abortus* 544) or were sacrificed by cervical dislocation to perform immunity tests. All experiments were conducted at least twice. The time of challenge and the time of sacrifice postchallenge (see below) were selected on the basis of previous studies (27, 28).

(iii) Protection assessment. Protection conferred by the experimental vaccines was evaluated essentially as described previously (11, 12). Thirty days after the challenge with virulent *Brucella* organisms, mice were sacrificed by cervical dislocation, their spleens were removed aseptically and homogenized, and dilutions were plated on bacteriological agar and incubated appropriately to determine the number of *Brucella* CFU per spleen. In the case of the control group immunized with viable *B. abortus* S19, spleen homogenates were cultured in parallel under selective (0.1% erythritol, an inhibitor of S19 strain growth) and nonselective conditions in order to differentiate the CFU from the immunization strain and the challenge strain. In all cases, units of protection were obtained by subtracting the mean log₁₀ CFU of the experimental group from the mean log₁₀ CFU of the corresponding negative-control group.

(iv) Antibody titers by ELISA. The titers of serum immunoglobulin G of isotypes 1 and 2a (IgG1 and IgG2a) with specificity to VirB7 or VirB9 were determined by an enzyme-linked immunosorbent assay (ELISA). Polystyrene plates (Nunc, Roskilde, Denmark) were coated with purified recombinant VirB7 or VirB9 (0.5 μg/well) in PBS during 1 h at room temperature. After this incubation, plates were washed four times with PBS with 0.05% Tween 20 (PBS-T) and blocked overnight at 4°C with 200 μl/well of PBS containing 3% skim milk. Then, plates were incubated with serial dilutions (starting at 1:1000) of sera for 1 h at room temperature and washed four times. Isotype-specific goat anti-mouse horseradish peroxidase conjugates (Santa Cruz Biotechnology, Santa Cruz, CA) were added (50 μl/well) at appropriate dilutions. After 1 h of incubation at room temperature, plates were washed four times, and 50 μl/well of substrate solution (200 μmol of o-phenylenediamine and 0.04% H₂O₂) were added to each well. After 20 min of incubation at room temperature, the enzyme reaction was stopped by the addition of 3 N H₂SO₄, and the OD was measured at 492 nm in a microplate reader (Multiskan). The cutoff value of the assay was calculated as the mean OD plus 3 standard deviations (SD) produced at a 1:100 dilution by sera obtained on day 0 from all mice. The specific titer of each serum was calculated as the reciprocal of the highest dilution that yielded an OD higher than the cutoff value.

(v) Determination of cytokine production. Spleen cells from immunized and control mice were homogenized and suspended in RPMI 1640.
medium (Gibco BRL; Life Technologies, Grand Island, NY) supplemented with 10% fetal calf serum (Gibco), 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U of penicillin/ml, and 100 μg of streptomycin/ml (complete medium). Cells were cultured at 5 × 10⁶ cells/ml in duplicate with VirB7 or VirB9 (1 or 10 μg/ml), concanavalin A (ConA) (5 μg/ml) (Sigma), or complete medium alone. Cultures were incubated at 37°C in a humidified atmosphere (5% CO₂ and 95% air) for 48 h. At the end of the incubation, cell culture supernatants were collected, aliquoted, and frozen at −70°C until analysis for cytokine levels. Gamma interferon (IFN-γ) and interleukin-4 (IL-4) levels were determined by a sandwich ELISA using paired cytokine-specific monoclonal antibodies (MAbs), according to the manufacturer’s instructions (BD Biosciences).

**Experiments in dogs.** (i) Animals. A total of 15 healthy dogs of different breeds (4 males and 11 females, ages 1 to 5 years [mean, 2.53 years]) were included in the study. Experiments in dogs were approved by our institutional animal care and use committee.

(ii) Immunization. Dogs were randomly divided into 3 groups of five animals each and were subcutaneously immunized with 1 ml of a mixture of 100 μg of VirB7 or VirB9 (or an equivalent volume of PBS) and 100 μg of QuilA adjuvant. Dogs received three subcutaneous doses of the antigens with QuilA adjuvant every 30 days, and blood samples were collected before immunization and then monthly between the first immunization and day 90 after the last immunization (150 days after the first dose) for the serological and cellular immunity studies.

(iii) Antibody titers. The titers of serum IgG specific for VirB7 or VirB9 were determined by an ELISA following the protocol described above for mice sera, but using a peroxidase-conjugated rabbit anti-dog IgG serum.

(iv) Determination of IFN-γ production. Mononuclear cells were purified from heparinized blood by the Ficoll-Hypaque method and cultured at 1 × 10⁶ cells/ml in duplicate with VirB7 or VirB9 (1 or 10 μg/ml), ConA (5 μg/ml), or complete medium alone. Cultures were incubated at 37°C in a humidified atmosphere (5% CO₂ and 95% air) for 48 h. At the end of the incubation, cell culture supernatants were collected, aliquoted, and frozen at −70°C until analyzed for canine IFN-γ by a sandwich ELISA using paired cytokine-specific MAbs, according to the manufacturer’s instructions (R&D Systems).

(v) Delayed-type hypersensitivity test. One month after the last immunization, delayed-type hypersensitivity (DTH) tests were performed as an index of cell-mediated immunity. A volume of 0.1 ml containing 10 μg of VirB7 or VirB9 was injected intradermally in the inner surface of the right thigh, and an equal volume of PBS was injected 3 cm apart as a negative control. The DTH reaction was quantified 48 h later by using a digital caliper with a precision of 0.01 mm to measure the size of the induration and erythematous area (mean of two perpendicular diameters). As described in similar studies in dogs (29), a reaction area of >5 mm was considered positive.

(vi) In vitro bacteriolysis assay. The assay was performed in flat-bottomed 96-well plates as described previously (30). B. canis suspensions were used at concentrations that did not agglutinate when mixed with sera from immunized dogs. Fifty microliters of a 1/2 dilution of heat-inactivated serum (56°C, 30 min) from each dog or a 1:1 mixture of pools of anti-VirB7 and anti-VirB9 sera was dispersed in duplicate in contiguous wells of the plate, followed by 50 μl of a B. canis suspension (1 × 10⁶ CFU/ml) in PBS containing 0.5 mM MgCl₂ and 0.15 mM CaCl₂. The mixtures were homogenized by placing the plate in an orbital shaker at 150 rpm during 90 min at 37°C to allow optimal interaction between the antibodies and bacteria. As a source of complement, 10 μl of guinea pig serum was added to each reaction, and the mixture was homogenized again in the orbital shaker at 150 rpm for 2 h at 37°C. At the end of this incubation, 25 μl of each reaction was plated in duplicate on tryptic soy agar to determine CFU numbers. Control reactions were as follows: (i) sera from immunized dogs plus bacterial suspension and heat-inactivated guinea pig serum, (ii) sera obtained from dogs before immunization plus bacterial suspension and guinea pig serum, and (iii) bacterial suspension plus guinea pig serum (no dog serum added).

Statistical analysis. CFU data were logarithmically transformed, and statistical analysis was conducted using analysis of variance (ANOVA) followed by Dunnett’s post hoc test. ANOVA followed by Bonferroni’s test was used to analyze humoral and cellular responses of immunized animals. DTH was evaluated by one-way analysis of variance, followed by Bonferroni’s multiple-comparison test. The analysis was performed using GraphPad software, version 4 (San Diego, CA).

**Results**

Immune response of mice to immunization with VirB proteins. Titers of IgG1 and IgG2a against VirB7 and VirB9 were determined at 30 days after the last immunization with VirB proteins (i.e., at the time of challenge with virulent brucellae). As shown in Fig. 1, specific IgG1 and IgG2a antibodies against both antigens were detected. The titers of all the antibodies increased along with time after immunization, although for both isotopes, the increase only reached statistical significance for anti-VirB9 antibodies.

Splenocytes from animals sacrificed at the time of challenge were stimulated in vitro with VirB proteins. As shown in Fig. 2, cells from animals immunized with VirB7 or VirB9 responded to their respective antigens with significant and specific production
of IFN-γ. In contrast, no specific secretion of IL-4 was detected in response to stimulation with any of the VirB proteins (data not shown).

Protection conferred by VirB immunization to challenge with live brucellae in mice. The production of IFN-γ (but not IL-4) by murine splenocytes in response to the in vitro stimulation with VirB antigens indicated that the immunization protocol used in this study induced a Th1-type specific immune response against VirB proteins. To assess the potential protection conferred by such a response, immunized mice were challenged with virulent VirB proteins. To assess the potential protection conferred by this immunization protocol used in the last two sampling times (120 and 150 days). Titters obtained from day 90 onward were significantly increased compared to those obtained at day 30. Antibodies against VirB9 showed an irregular but steady increase of titters until the end of the follow-up. However, only titters obtained at day 150 were significantly increased compared to those obtained at day 30, probably due to the dispersion of values obtained at each time point. At day 150, mean IgG titters against VirB7 and VirB9 were 5.6- and 18.3-fold higher than their respective titters at 30 days postimmunization.

Bacteriolytic activity of anti-VirB antibodies. Previous studies have shown that specific antibodies can bind to proteins expressed in the membrane of rough Brucella microorganisms (B. canis and B. ovis) (33). Moreover, antibodies against the outer membrane protein Omp31 can mediate complement-dependent bacteriolysis of B. ovis (34). As VirB7 and VirB9 are predicted to be associated to the outer membrane of Brucella, we decided to test whether the anti-VirB antibodies present in the sera of immunized dogs may mediate complement-dependent bacteriolysis of B. canis in vitro. The bacteria were incubated with either preimmune or immune sera from each dog and with guinea pig serum added as a source of complement before plating for CFU counting. As shown in Fig. 4, incubation with sera from the PBS control group did not reduce the CFU numbers of B. canis compared to those observed in reactions with preimmune sera. In contrast, incubation with sera from dogs immunized with VirB7 or VirB9 resulted in a significant reduction of CFU numbers. The involvement of complement in such a reduction was corroborated by perfor-

![FIG 2 IFN-γ secretion by spleen cells from immunized mice in response to in vitro stimulation with VirB antigens.](http://cvi.asm.org)

**TABLE 1 Protection against B. abortus infection in mice by immunization with VirB proteins**

| Immunogen | Splenic Brucella load (mean ± SD) (log CFU/spleen) | Protection (log) | Splenic wt (mean ± SD) (g) |
|-----------|-----------------------------------------------|-----------------|----------------------------|
| VirB7     | 4.43 ± 0.44                                  | 0.87<sup>a</sup> | 1.07 ± 0.03                |
| VirB9     | 4.50 ± 0.34                                  | 0.80<sup>a</sup> | 1.31 ± 0.22                |
| H38       | 3.64 ± 0.46                                  | 1.66<sup>b</sup> | 0.76 ± 0.04                |
| S19       | 3.48 ± 0.44                                  | 1.82<sup>c</sup> | 1.06 ± 0.05                |
| PBS       | 5.30 ± 0.21                                  | 0.00            | 1.07 ± 0.49                |

<sup>a</sup> Mice were immunized twice (15 days apart) with VirB7 or VirB9 (the first dose with complete Freund adjuvant; the second dose with incomplete Freund adjuvant) or were immunized once with heat-killed B. melitensis H38 or live B. abortus S19 and were challenged 30 days later with B. abortus S44 through the intraperitoneal route. Mice were sacrificed 30 days later to determine their splenic load of B. abortus S44. Splenic loads are expressed as means ± SD of log CFU per spleen. For each immunization group, protection was calculated as the difference of mean splenic load between that group and the nonimmunized (PBS) group (ANOVA followed by Dunnett’s test).

<sup>b</sup> P < 0.1.

<sup>c</sup> P < 0.05.

<sup>d</sup> P < 0.001.
mance of the same assays but with heat-treated guinea pig serum. In addition, complement did not produce any direct bacterioytic effect on *B. canis* as demonstrated by the lack of CFU reduction when bacteria were incubated with complement alone (guinea pig serum) in the absence of dog serum. As both anti-VirB7 and anti-VirB9 antibodies produced complement-mediated bacteriolysis, we decided to test whether a 1:1 mixture of both types of sera produces a higher bacteriolysis degree than that induced by each serum alone. As shown in Fig. 4, the reduction in CFU numbers obtained with the mixture did not differ significantly from that obtained with each serum alone. It must be noted that the concentration of each serum in the mixture was the same as that present in reactions performed with each serum separately, as a 1/2 dilution was used in the latter cases.

**In vitro cellular immune response.** The ability of peripheral blood lymphocytes from immunized dogs to secrete IFN-γ in response to the recognition of peptides derived from VirB proteins was assessed *in vitro*. As shown in Fig. 5, upon *in vitro* stimulation with VirB7 or VirB9, peripheral blood mononuclear cells (PBMCs) from immunized dogs produced IFN-γ levels significantly higher than those produced by cells from the control group. The IFN-γ levels produced specifically in response to each VirB protein were similar.

![Graph showing serum antibody titers against VirB7 and VirB9 in immunized dogs.](http://cvi.asm.org/)

**DISCUSSION**

Since *Brucella* spp. are intracellular pathogens, which mainly reside in macrophages and dendritic cells, cellular immune responses are fundamental for protective immune responses. The IFN-γ-mediated activation of macrophages is a central component of this immune protection (18). Therefore, the identification of *Brucella* antigens that can induce a specific Th1-type response with production of IFN-γ may contribute to the development of efficacious vaccines against brucellosis. To our best knowledge, the potential usefulness of VirB proteins as vaccine candidates has not been explored.

The expression of virB genes is induced intracellularly after *Brucella* phagocytosis (24, 25). As most *Brucella* cells die shortly after phagocytosis, before the establishment of the intracellular replication niche, infected macrophages may display peptides derived from *Brucella* VirB proteins in the context of MHC-II. Thus, the elicitation of VirB-specific Th1 cells by specific immunization
may allow the recognition of infected macrophages, leading to the production of IFN-γ and the activation of macrophagic antimicrobial mechanisms.

In the present study, we have found that mice immunized with VirB7 or VirB9 mixed with Freund’s adjuvant develop a Th1-biased immune response as revealed by the secretion of IFN-γ (but not IL-4) by spleen cells stimulated with these antigens. Notably, when these mice were challenged with live B. abortus through the intraperitoneal route, they exhibited a significant reduction of bacterial load in the spleen compared to that of the nonimmunized controls. The reduction level attained is similar to that obtained in the mouse model in previous studies with Brucella proteins (12). These results agree with our working hypothesis regarding the potential protective role of VirB-specific Th1 cells and strongly suggest that immunization with VirB proteins may constitute an effective approach to protect animals from Brucella infection.

Whereas the mouse model has been extensively used to study several aspects of Brucella infection and to test candidate antigens for the potential development of vaccines, it must be kept in mind that the mouse is not a natural host for Brucella infection. While several studies have been performed in natural hosts to test the protective efficacy of immunization with attenuated strains of Brucella, only a few studies have been performed with acellular Brucella vaccines, and only one has employed a purified antigen (30, 35). We considered a test of whether an adequate anti-VirB Th1-type response can be elicited in a natural host of Brucella particularly important. Dogs were chosen for this purpose for several reasons, including not only the easy handling of these animals but also the current lack of vaccines for canine brucellosis.

Canine infection by B. canis, which can be transmitted among dogs by venereal and oral routes, can spread rapidly within kennels, and given the limited efficacy of antimicrobials mentioned above, usually requires the castration or the euthanasia of the affected animals, with the consequent economic loss (36). Cases of human infection by B. canis have been increasingly reported among owners of infected dogs (37). Despite the economic and environmental costs associated with canine brucellosis and the potential for human infection, there are currently no effective vaccines available for this disease. Our results suggest that immunization with VirB proteins may represent a promising approach to protect dogs and potentially reduce the incidence of canine brucellosis.

**FIG 5** In vitro IFN-γ production by peripheral mononuclear cells (PBMCs) of dogs immunized with VirB proteins. PBMCs from dogs immunized with either VirB7 or VirB9 were obtained 1 month after the third immunization and were incubated for 48 h with the corresponding antigen or concanavalin A (ConA) or were left unstimulated to determine basal secretion. PBMCs obtained from dogs receiving PBS (control group) were treated in the same manner to determine the specificity of the measured response. IFN-γ levels were measured in culture supernatants using a commercial sandwich ELISA. The data represent means and SD of values determined in duplicate for each of the 5 dogs in each group. The asterisks indicate significant differences between VirB-stimulated cells and unstimulated cells of the same group, and the dots indicate significant differences between immunization groups regarding the response to the same stimulus. (*, P < 0.05, and ●, P < 0.05, ANOVA followed by Bonferroni’s test). The figure shows a representative experiment of two performed with similar results.

**TABLE 2** DTH reactions against VirB proteins in immunized dogs

| Dog | Sex | Age (yr) | Breed | Immunization group | Challenge 1 | Challenge 2 |
|-----|-----|----------|-------|--------------------|-------------|-------------|
|     |     |          |       |                    | Antigen     | DTH (mm)    | Antigen     | DTH (mm)    |
| 1   | F   | 5        | W     | PBS                | VirB7       | 11 × 11     | VirB9       |             |
| 2   | M   | 4        | G     | PBS                | VirB7       | 9 × 11      | VirB9       |             |
| 3   | F   | 1        | G     | PBS                | VirB7       | 9 × 11      | VirB9       |             |
| 4   | F   | 5        | B     | PBS                | VirB7       | 9 × 11      | VirB9       |             |
| 5   | F   | 6        | S     | PBS                | VirB7       | 9 × 11      | VirB9       |             |
| 6   | M   | 1        | B     | VirB7              | VirB7       | 11 × 11     | VirB9       |             |
| 7   | F   | 2        | F     | VirB7              | VirB7       | 9 × 11      | VirB9       |             |
| 8   | F   | 2        | B     | VirB7              | VirB7       | 9 × 11      | VirB9       |             |
| 9   | F   | 3        | B     | VirB7              | VirB7       | 9 × 11      | VirB9       |             |
| 10  | M   | 2        | B     | VirB7              | VirB7       | 9 × 11      | VirB9       |             |
| 11  | F   | 1        | F     | VirB9              | VirB9       | 8 × 11      | VirB9       |             |
| 12  | F   | 1        | F     | VirB9              | VirB9       | 8 × 11      | VirB9       |             |
| 13  | F   | 2        | B     | VirB9              | VirB9       | 8 × 11      | VirB9       |             |
| 14  | F   | 3        | B     | VirB9              | VirB9       | 8 × 11      | VirB9       |             |
| 15  | M   | 2        | S     | VirB9              | VirB9       | 8 × 11      | VirB9       |             |

a Dogs from the different immunization groups were intradermally injected with VirB proteins and/or an equal volume of PBS in the inner surface of the right thigh. The DTH reaction was evaluated 48 h later by measuring the size (two perpendicular diameters) of the induration. A reaction area larger than 5 mm (average of the two perpendicular measures) was considered positive.

b W, Weimaraner; G, golden retriever; B, beagle; F, French bulldog; S, miniature schnauzer.
health impact of canine brucellosis, no vaccines are available to prevent this disease. Histological studies performed in dogs have shown that *B. canis*, as for other *Brucella* species, is an intracellular pathogen (38, 39). It establishes mainly in macrophages from secondary lymphatic organs and in epithelial cells from steroid-sensitive organs (prostate, testicles, uterus, and placenta). Therefore, a vaccine eliciting a specific Th1-type immune response with the production of IFN-γ is desirable. *Brucella* VirB proteins may be relevant antigens in canine brucellosis. A recent study has shown the presence of the 12 genes of the virB operon in more than 30 isolates of *B. canis* (40). Such an operon is functional, as *B. canis* strains carrying deletions or disruptions in such genes have reduced virulence in mice (41). Therefore, *B. canis*-infected cells are expected to present VirB-derived peptides in the context of MHC-II, and anti-VirB Th1 cells are expected to exert a protective role against *B. canis* infection.

In the present study, we found that PBMCs from dogs immunized with VirB7 or VirB9 mixed with QuilA adjuvant produce IFN-γ upon stimulation with these antigens, suggesting the elicitation of a VirB-specific Th1-type response. Moreover, an *in vivo* correlate of Th1-type response was also detected, since most immunized dogs had a positive DTH response to both VirB antigens. While the production of IFN-γ by antigen-specific Th1 cells may have central importance for protection against *B. canis* infection, antibodies may also have a role. *B. canis* is a naturally rough strain, a character shared only by *B. ovis* within the *Brucella* genus (all the other species are naturally smooth). The molecular basis for this differential character is the lack of the O polysaccharide chain in *B. canis* and *B. ovis* LPS, which may leave outer membrane proteins (OMPs) more accessible to circulating antibodies. Notably, previous studies have shown that specific antibodies bind to OMPs of rough *Brucella* microorganisms (33). Moreover, it has been shown that antibodies against the outer membrane protein Omp31 can mediate complement-dependent bacteriolysis of *B. ovis* (34). *In vivo*, this lytic mechanism might have a protective role during the bacteremic phase of the infection before the entry of bacteria in their target cells. Notably, we found that sera from VirB-immunized dogs mediate complement-dependent bacteriolysis of *B. canis* cells. This effect was most probably mediated by anti-VirB antibodies since no bacteriolysis was observed with sera obtained from these dogs before immunization with VirB proteins. A direct effect of complement was also ruled out since no lysis was detected when bacteria were incubated with guinea pig serum in the absence of dog serum. While both anti-VirB7 and anti-VirB9 sera mediated the complement-dependent bacteriolysis, the degree of bacteriolysis did not increase when the assay was performed with a 1:1 mixture of these sera. This is probably because VirB7 and VirB9 locate very closely in the membrane of *Brucella* species, so that the binding of specific antibodies to one of these proteins may hinder the binding of antibodies to the other.

Collectively, the results obtained in the present study suggest that it may be possible to elicit an immune response potentially protective against *B. canis* infection in dogs through immunization with VirB7 and/or VirB9 mixed with QuilA adjuvant. The protocol used elicited both cellular and humoral immune responses that may mediate protective mechanisms. As both VirB proteins are present in all the *Brucella* species, a vaccine based on these antigens may also confer protection against brucellosis to other hosts.

**ACKNOWLEDGMENTS**

We thank the staff of the Centro Nacional de Referencia del Sida, University of Buenos Aires, for their assistance with biosafety level 3 laboratory use. We thank Sergio Islas (CIC) and Fabián Amaya and Adrián Pérez (FCV, UNCPBA, Argentina) for animal care. We thank María del Carmen Villar for offering her dogs for the vaccination experiment. This work was supported by grants PICT2005-38237 and PICT2006-0517 from the Agencia Nacional de Promoción Científica (ANPCYT) and grant UBACYT B105 from the Universidad de Buenos Aires. C.N.P. is the recipient of a research fellowship from the Consejo Nacional de Investigaciones Científicas (CONICET). M.V.D., C.A.F., S.M.E., and P.C.B. are members of the Research Career of CONICET. We declare no conflicts of interest.

**REFERENCES**

1. Pappas G, Akrithidis N, Bosilkovski M, Tsianos E. 2005. Brucellosis. N Engl J Med 352:2325–2336. http://dx.doi.org/10.1056/NEJMra050570.
2. Brower A, Okwumabua O, Massengill C, Muenks Q, Vanderloo P, Duster M, Homb K, Kurth K. 2007. Investigation of the spread of *Brucella canis* via the U.S. interstate dog trade. Int J Infect Dis 11:454–458. http://dx.doi.org/10.1016/j.ijid.2006.12.009.
3. Hollett RB. 2006. Canine brucellosis: outbreaks and compliance. Theriogenology 66:575–587. http://dx.doi.org/10.1016/j.theriogenology.2006.04.001.
4. Booth BS, Löfqvist K, Ernholm L, Eld K, Cedersmyg M, Hallgren G. 2012. The first case of *Brucella canis* in Sweden; background, case report and recommendations from a Northern European perspective. Acta Vet Scand 54:18. http://dx.doi.org/10.1186/1751-0414-5-18.
5. Lucero NE, Corazza R, Almazura MN, Reynolds E, Escobar GI, Boeri A, Ayalà SM. 2010. Human *Brucella canis* outbreak linked to infection in dogs. Epidemiol Infect 138:280–325. http://dx.doi.org/10.1017/S0950268809995525.
6. Munford RS, Weaver RE, Patton C, Feeley JC, Feldman RA. 1975. Human disease caused by *Brucella canis*. A clinical and epidemiologic study of two cases. JAMA 231:1267–1269.
7. Blasco JM, Díaz R. 1993. *Brucella melitensis* Rev-1 vaccine as a cause of human brucellosis. Lancet 342:805. http://dx.doi.org/10.1016/0140-6736(93)91517-3.
8. Ashford DA, di Pietra J, Lingappaj J, Woods C, Noll H, Neville B, Weyant R, Bragg SL, Spiegel RA, Tappero J, Perkins BA. 2004. Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51. Vaccine 22:3433–3439. http://dx.doi.org/10.1016/j.vaccine.2004.02.041.
9. Wallach JC, Ferrero MC, Delpino MV, Fossati CA, Baldi PC. 2008. Oral vaccination with *Brucella abortus* S19 among workers involved in vaccine production in Argentina. Clin Microbiol Infect 14:805–807. http://dx.doi.org/10.1111/j.1469-0691.2008.02029.x.
10. Oliveira SC, Splitter GA. 1996. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against *Brucella abortus* infection. Vaccine 14:959–962. http://dx.doi.org/10.1016/0264-410X(96)00018-7.
11. Estein SM, Cassataro J, Vizzacino N, Zygmont MS, Cloeckaert A, Bowden RA. 2003. The recombinant Omp31 from *Brucella melitensis* alone or associated with rough lipopolysaccharide induces protection against *Brucella ovis* infection in BALB/c mice. Microbes Infect 5:85–93. http://dx.doi.org/10.1016/S1286-4579(02)00007-5.
12. Delpino MV, Estein SM, Fossati CA, Baldi PC, Cassataro J. 2007. Vaccination with *Brucella* recombinant DNA and SRA proteins induces protection against *Brucella abortus* infection in BALB/c mice. Vaccine 25:6721–6729. http://dx.doi.org/10.1016/j.vaccine.2007.07.002.
13. Velkovksy CA, Cassataro J, Giambartolomei GH, Goldbaum FA, Estein SM, Bowden RA, Bruno L, Fossati CA, Spitz M. 2002. A DNA vaccine encoding lumazine synthase from *Brucella abortus* induces protective immunity in BALB/c mice. Infect Immun 70:2507–2511. http://dx.doi.org/10.1128/IAI.70.5.2507–2511.2002.
14. Cassataro J, Velkovsksy CA, de la Barrera S, Estein SM, Bruno L, Bowden R, Pasquichka KA, Fossati CA, Giambartolomei GH. 2005. A DNA vaccine coding for the *Brucella* outer membrane protein 31 confers protection against *B. melitensis* and *B. ovis* infection by eliciting a specific cytotoxic response. Infect Immun 73:6537–6546. http://dx.doi.org/10.1128/IAI.73.10.6537–6546.2005.
15. Luo D, Ni B, Li P, Shi W, Zhang S, Han Y, Mao L, He Y, Wu Y, Wang
X. 2006. Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice. Infect Immun 74:2734–2741. http://dx.doi.org/10.1128/IAI.74.5.2734-2741.2006.

16. Celli J. 2006. Surviving inside a macrophage: the many ways of Brucella. Res Microbiol 157:93–98. http://dx.doi.org/10.1016/j.resmic.2005.10.002.

17. Roop RM, II, Gaines JM, Anderson ES, Caswell CC, Martin DW. 2009. Survival of the fittest: how Brucella strains adapt to their intracellular niche in the host. Med Microbiol Immunol 198:221–238. http://dx.doi.org/10.1007/s00430-009-0123-8.

18. Baldwin CL, Goenga R. 2006. Host immune responses to the intracellular bacteria Brucella: does the bacteria instruct the host to facilitate chronic infection? Crit Rev Immunol 26:407–442. http://dx.doi.org/10.1615/CritRevImmunol.v26.i3.50.

19. Al-Mariri A, Ibañez AE, Barrionuevo P, Oliveira FS, Carvalho NB, Borkowski J, Oliveira SC, Warzecha H, Giambartolomei GH, Cassataro J. 2010. The protein moiety of Brucella abortus outer membrane protein 16 is a new bacterial pathogen-associated molecular pattern that activates dendritic cells in vivo, induces a Th1 immune response, and is a promising self-adjuvanting vaccine against systemic and oral acquired brucellosis. J Immunol 184:5200–5212. http://dx.doi.org/10.4049/jimmunol.090209.

20. Borja-Cabrera GP, Correia Pontes NN, da Silva VO, Paraguai de Souza E, Santos WR, Goes E, Iurz KG, Patrut KM, Patrut de Sousa CB. 2002. Long lasting protection against canine kala-azar using the FML-QuA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine 20:3277–3284. http://dx.doi.org/10.1016/S0264-410X(02)00294-3.

21. Stein SM, Fiorentino MA, Paolicchi FA, Clausse M, Manazza J, Cassataro J, Giambartolomei GH, Coria LM, Zylberman V, Fossati CA, Kijek R, Goldbaum FA. 2009. The polymeric antigen BLSomp31 confers protection against Brucella ovis infection in rams. Vaccine 27:6704–6711. http://dx.doi.org/10.1016/j.vaccine.2009.08.097.

22. Grilló MJ, Manterola L, de Miguel MJ, Muñoz PM, Blasco JM, Moriyón I, López-Goni I. 2006. Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants. Vaccine 24:2910–2916. http://dx.doi.org/10.1016/j.vaccine.2005.12.038.

23. Spickler AR, Roth JA. 2003. Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med 17:273–281. http://dx.doi.org/10.1111/j.1365-3052.2003.02448.x.

24. Bowden RA, Cloeckaert A, Zygmont MS, Bernard S, Durbay G. 1995. Surface exposure of outer membrane protein and lipopolysaccharide epitopes in Brucella species studied by enzyme-linked immunosorbent assay and flow cytometry. Infect Immun 63:3945–3952.

25. E. Tenorio-Gutiérrez V, Salas-Téllez E, Suárez-Güemes F, Díaz-Aparicio L, Martínez-Garro J, Muñoz PM, Estevan M, Marín CM, Jesús De Miguel M, Jesús Grilló M, Barberán M, Irape JM, Blasco JM, Gamazo C. 2006. Brucella outer membrane complex-loaded microparticles as a vaccine against Brucella abortus in rams. Vaccine 24:1897–1905. http://dx.doi.org/10.1016/j.vaccine.2005.10.005.

26. Danon MM. 2004. Canine brucellosis. Anim Reprod Sci 82-83:193–207. http://dx.doi.org/10.1016/j.anireprosci.2004.05.004.

27. Marzetti S, Carranza C, Roncallo M, Escobar GI, Lucero NE. 2013. Recent trends in human Brucella canis infection. Comp Immunol Microbiol Infect Dis 36:55–61. http://dx.doi.org/10.1016/j.cimid.2012.09.002.

28. Carmichael LE, Kenney RM. 1968. Canine abortion caused by Brucella canis. J Am Vet Med Assoc 152:605–616.

29. Gyuranecz M, Szeredi L, Rónai Z, Dénes B, Dencso L, Dán Á Pálmai N, Grilló MJ, García Samartino C, Coria LM, Estein SM, Zwerdling KA, García Samartino C, Desaphy J, Kenney RM. 2003. Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med 17:273–281. http://dx.doi.org/10.1111/j.1365-3052.2003.02448.x.

30. de la Cuesta-Zuluaga JJ, Martínez-Jiménez MM, Martínez-Garro J, Oli- vera-Angel M. 2013. Identification of the virB operon genes encoding the type IV secretion system, in Colombian Brucella canis isolates. Vet Microbiol 163:196–199. http://dx.doi.org/10.1016/j.vetmic.2012.12.008.

31. Palomares-Resendiz E, Arellano-Reynoso B, Hernández-Castro R, Tenorio-Gutiérrez V, Salas-Téllez E, Suárez-Guijueses A, Díaz-Aparicio E. 2012. Immunogenic response of Brucella canis virB10 and virB11 mutants in a murine model. Front Cell Infect Microbiol 2:35. http://dx.doi.org/10.3389/fcimb.2012.00035.